Review: Suicide and schizophrenia: a systematic review of rates and risk factors, J Psychopharmacol, vol.24, pp.81-90, 2010. ,
Absolute Risk of Suicide After First Hospital Contact in Mental Disorder, Arch Gen Psychiatry, vol.68, issue.10, p.1058, 2011. ,
,
Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review, 11e ,
, The AmpliChip TM CYP450 Genotyping Test. Mol Diag Ther. 1 mai, vol.10, issue.3, pp.135-51, 2006.
Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J. févr, vol.5, issue.1, pp.6-13, 2005. ,
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006. ,
Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, vol.41, issue.12, pp.913-58, 2002. ,
Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet, vol.56, pp.247-58, 1999. ,
Phenome-wide and Genomewide Analyses of Quality of Life in Schizophrenia ,
Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort, JCM. 10 août, vol.8, issue.8, p.1196, 2019. ,
Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene, Mol Psychiatry. juin, vol.19, issue.6, pp.733-774, 2014. ,
Association between CYP2C19 polymorphism and depressive symptoms, Am J Med Genet B Neuropsychiatr Genet. sept, vol.153, issue.6, pp.1160-1166, 2010. ,
Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review, 11e ,
Consensus Guidelines for Therapeutic Drug Monitoring in Neuro psychopharmacology: Update, Pharmacopsychiatry. janv, vol.51, issue.1-02, pp.9-62, 2017. ,
Psychiatric pharmacogenomic testing in clinical practice, Dialogues Clin Neurosci, vol.12, issue.1, pp.69-76, 2010. ,
De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients, The pharmacogenomics journal. 1 déc, vol.7, pp.408-418, 2007. ,
Description du polymorphisme génétique des cytochromes P450 2C19 et 2D6 (CYP2C19 et CYP2D6) d'une large cohorte franc?aise de patients suivis en psychiatrie, vol.53, 2019. ,
The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-76, 1987. ,
Validity and reliability of the Frenchlanguage version of the Positive and Negative Syndrome Scale (PANSS), Acta Psychiatr Scand. sept, vol.100, issue.3, pp.237-280, 1999. ,
Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry Suppl. déc, issue.22, pp.39-44, 1993. ,
,
, Encephale. févr, vol.26, issue.1, pp.52-61, 2000.
An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution, Hum Genet. mars, vol.95, issue.3, pp.337-378, 1995. ,
Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005. ,
Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002. ,
The star-allele nomenclature: retooling for translational genomics, Clin Pharmacol Ther. sept, vol.82, issue.3, pp.244-252, 2007. ,
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clin Pharmacol Ther. août, vol.98, issue.2, pp.127-161, 2015. ,
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008. ,
Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics, Disponible sur, vol.17, 2018. ,
Discrepancy between subjective and objective ratings for negative symptoms, J Psychiatr Res. févr, vol.34, issue.1, pp.11-14, 2000. ,
Negative symptoms in depressed and schizophrenic patients: how do they differ?, J Clin Psychiatry. août, vol.64, issue.8, pp.954-962, 2003. ,
Negative symptoms in schizophrenia: a review, Nord J Psychiatry, vol.62, issue.5, pp.334-375, 2008. ,
Suicide Ideation and Behavior as Risk Factors for Subsequent Suicide in Schizophrenia: A Nested Case-Control Study, Suicide Life Threat Behav. août, vol.49, issue.4, pp.996-1005, 2019. ,
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004. ,
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study, Lancet Psychiatry. mai, vol.6, issue.5, pp.418-444, 2019. ,
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Molecular Psychiatry, vol.22, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01798313
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6, Acta Psychiatr Scand. janv, vol.87, issue.1, pp.23-31, 1993. ,
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations, Expert Opinion on Drug Metabolism & Toxicology. nov, vol.10, issue.11, pp.1569-83, 2014. ,
Dopamine formation from tyramine by CYP2D6, Biochem Biophys Res Commun. 28 août, vol.249, issue.3, pp.838-881, 1998. ,
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6, Pharmacogenetics. mars, vol.13, issue.3, pp.173-81, 2003. ,
Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6, Brain Res Mol Brain Res, vol.129, issue.1-2, pp.117-140, 2004. ,
The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders, Drug Metab Rev, vol.50, issue.4, pp.415-444, 2018. ,
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia, Psychiatr Genet, vol.8, issue.1, pp.25-33, 1998. ,
Lack association between schizophrenia and the CYP2D6 gene polymorphisms, Am J Med Genet. 9 avr, vol.67, issue.2, pp.236-243, 1996. ,